19
Participants
Start Date
April 30, 2001
Primary Completion Date
July 31, 2001
Study Completion Date
July 31, 2001
BIA 3-202
"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
Placebo
Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
Sinemet 25/100
Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.
Human Pharmacology Unit - BIAL - Portela & Ca, S.A., S. Mamede Do Coronado
Bial - Portela C S.A.
INDUSTRY